Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study. (30th March 2017)

• Record Type: Journal Article
• Authors: Tsai, Joyce; Thase, Michael E.; Mao, Yongcai; Ng-Mak, Daisy; Pikalov, Andrei; Loebel, Antony
• Editors: McIntyre, Roger
• Is Part Of: CNS spectrums. Volume 22:Number 2(2017:Apr.)
• Page Start: 236
• Page End: 245
• Publication Date: 2017-03-30
• Subjects: Major depressive disorder, -- mixed features, -- atypical antipsychotic, -- lurasidone, -- anxiety; Neuropsychiatry -- Periodicals; Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; 616.8005
• DOI: 10.1017/S1092852917000074
• Languages: English
• ISSNs: 1092-8529

Abstract

Abstract : Objective: The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating patients with major depressive disorder (MDD) with mixed features who present with mild and moderate-to-severe levels of anxiety. Methods: The data in this analysis were derived from a study of patients meeting the DSM–IV–TR criteria for unipolar MDD, with a Montgomery–Åsberg Depression Rating Scale (MADRS) total score ≥26, presenting with two or three protocol-defined manic symptoms, who were randomized to 6 weeks of double-blind treatment with either lurasidone 20–60 mg/day ( n =109) or placebo ( n =100). Anxiety severity was evaluated using the Hamilton Anxiety Rating Scale (HAM–A). To evaluate the effect of baseline anxiety on response to lurasidone, the following two anxiety groups were defined: mild anxiety (HAM–A≤14) and moderate-to-severe anxiety (HAM–A≥15). Change from baseline in MADRS total score was analyzed for each group using a mixed model for repeated measures. Results: Treatment with lurasidone was associated with a significant week 6 change versus placebo in MADRS total score for patients with both mild anxiety (–18.4 vs. –12.8, p <0.01, effect size [ ES ]=0.59) and moderate-to-severe anxiety (–22.0 vs. –13.0, p <0.001, ES =0.95). Treatment with lurasidone was associated with a significant week 6 change versus placebo in HAM–A total score for patients with both mild anxiety (–7.6 vs. –4.0, p <0.01, ES =0.62), and moderate-to-severe anxiety (–11.4 vs. –6.1, p <0.0001, ES =0.91). Conclusions: In this post-hoc analysis of an MDD with mixed features and anxiety population, treatment with lurasidone was associated with significant improvement in both depressive and anxiety symptoms in subgroups with mild and moderate-to-severe levels of anxiety at baseline.